Angela Thedinga
Director/Board Member presso NKARTA, INC.
Patrimonio netto: - $ in data 31/03/2024
Profilo
Angela M.
Thedinga is an Independent Director at Nkarta, Inc. She was previously the Chief Technology Officer at Adverum Biotechnologies, Inc. from 2020 to 2021 and the Chief of Staff & VP-Program Management at Novartis Gene Therapies, Inc. from 2018 to 2019.
Ms. Thedinga has a graduate degree from Massachusetts Institute of Technology, an undergraduate degree from the University of Wisconsin, a graduate degree from The University of North Carolina at Chapel Hill, and an MBA from MIT Sloan School of Management.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
NKARTA, INC.
-.--% | 14/04/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Angela Thedinga
| Società | Posizione | Inizio |
|---|---|---|
| NKARTA, INC. | Director/Board Member | 28/03/2022 |
Precedenti posizioni note di Angela Thedinga
| Società | Posizione | Fine |
|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Chief Tech/Sci/R&D Officer | 01/10/2021 |
| AVEXIS INC | Human Resources Officer | 01/06/2019 |
Formazione di Angela Thedinga
| Massachusetts Institute of Technology | Graduate Degree |
| University of Wisconsin | Undergraduate Degree |
| The University of North Carolina at Chapel Hill | Graduate Degree |
| MIT Sloan School of Management | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| NKARTA, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
- Borsa valori
- Insiders
- Angela Thedinga
